Command Hospital Kolkata Administers Indigenous CAR-T Therapy NexCAR19 to a Soldier

On 5 October 2026, Command Hospital (Eastern Command) in Kolkata administered NexCAR19, India's indigenous CAR-T cell therapy, to a 39-year-old serving soldier with relapsed/refractory B-cell acute lymphoblastic leukaemia (B-cell ALL). As of 7 October 2026 the administration is a completed event. It matters because it shows an indigenously developed cell therapy being used in a military hospital setting, and because it brings several science-and-technology concepts together for exam preparation.

Command Hospital Kolkata CAR-T case: key facts

The event date and the report date differ by two days, so use 5 October 2026 as the date of administration.

What CAR-T therapy is

How the treatment works

CAR-T stands for chimeric antigen receptor T-cell therapy, a type of immunotherapy. T cells, a kind of white blood cell involved in immune defence, are collected from the patient and genetically modified to produce a chimeric antigen receptor. They are then multiplied and infused back into the patient so they can recognise and attack cancer cells.

The CD19 target

NexCAR19 targets CD19, a protein on the surface of many B cells, including some cancerous ones. B-cell ALL is a cancer involving immature B lymphocytes, which is why a CD19-directed therapy applies to it.

Relapsed and refractory

• Relapsed: the cancer has returned after treatment.
• Refractory: the cancer has not responded adequately to treatment.

NexCAR19: development and reported features

The source describes NexCAR19 as India's first indigenous CAR-T cell therapy. It was developed with IIT Bombay, the Tata Memorial Centre and the biotechnology start-up ImmunoACT, as an immunotherapy option for blood cancers such as leukaemia and lymphoma.

The source also reports two further points:

• NexCAR19 has a humanised product configuration. According to the source, humanised components are associated with a lower risk of severe neurological side effects than murine (mouse-derived) components, which can provoke immune reactions against the treatment.
• Its estimated cost is about one-tenth that of similar therapies in Western countries. This is an estimate, and the source gives no rupee figure or comparison method.

Link to the Chandimandir administration

The source says the Kolkata administration followed a similar treatment at Command Hospital (Western Command) in Chandimandir in September 2026. That patient was a 16-year-old with the same condition. The evidence gives no exact September date. Command Hospitals are described as among the institutions authorised to administer this therapy.

Exam-relevant context

These points are useful for science and technology, health and defence-related current affairs. This is a study guide, not a prediction that any question will be asked.

• CAR-T therapy modifies a patient's own T cells so they recognise cancer cells.
• CD19 is the target antigen for NexCAR19 and is found on many B cells.
• Leukaemia is a cancer of blood-forming tissues, including bone marrow.
• NexCAR19 involved IIT Bombay, the Tata Memorial Centre and ImmunoACT.
• Command Hospital (Eastern Command) is in Kolkata, and Command Hospital (Western Command) is in Chandimandir.

Why blood cancers are the focus

A 2019 meta-analysis in Disease Markers noted that CAR-T therapy had achieved unprecedented success in haematologic tumours, while its role in solid tumours was unclear. It pooled 22 studies with 262 patients, with a literature search up to 1 June 2018. It found a pooled response rate of 9% in solid tumours. That study concerns solid tumours and is not about NexCAR19 or the Kolkata case. It only shows why CAR-T is mainly discussed for blood cancers such as B-cell ALL, and its findings may not reflect later research.

What the evidence does not tell us

• No treatment outcome, recovery status or follow-up for the Kolkata patient is reported, so no claim about effectiveness can be made.
• The account of the event rests on one secondary news source. The supplied evidence includes no official statement from the hospital, the armed forces or the developers.
• The exact September date of the Chandimandir case, the number of authorised centres and the actual treatment cost are not given.
• The "first indigenous" description and the cost comparison are the source's claims and are not independently verified here.

FAQ

When was NexCAR19 administered at Command Hospital Kolkata?

The source reports 5 October 2026. It was published on 7 October 2026.

Which condition was the therapy used for?

Relapsed/refractory B-cell acute lymphoblastic leukaemia in a 39-year-old serving soldier.

Who developed NexCAR19?

According to the source, its development involved IIT Bombay, the Tata Memorial Centre and ImmunoACT.